Vitravene (fomivirsen)
- Region
- 🇪🇺 EU
- Active substance
- fomivirsen
- Company
- Novartis Ophthalmics Europe Ltd.
- Status
- Withdrawn
- Therapeutic area
- Cytomegalovirus Retinitis; HIV Infections
- EU approval
- Thu 29 Jul 1999
- Application
- EMEA/H/C/000244
- ATC
- S01AD08
- Official record
- www.ema.europa.eu
Indication
For the local treatment of cytomegalovirus (CMV) retinitis in patients with acquired immuno-deficiency syndrome (AIDS). Until further experience is gained, fomivirsen should be used only when other therapy has been ineffective or is considered unsuitable.
Regulatory milestones
No milestones recorded in the last year.
Follow Vitravene
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.